Caris Molecular Tumor Board
The Caris Molecular Tumor Board provides oncologists with the opportunity to interact with leading cancer experts from across the country to obtain interpretation of molecular findings and therapeutic guidance for individual patients.
Collaborative Cancer Treatment
The Caris Molecular Tumor Board™ (CMTB) is an on-demand platform where clinicians, pathologists and scientists interact with leading cancer experts across the country. Through the CMTB, clinicians receive information and assistance to decipher complex data and molecular findings for difficult-to-treat patient cases. Specialists review each de-identified case and provide therapeutic guidance so clinicians can make the best possible treatment decisions for their patients. The CMTB provides oncologists with the opportunity to interact with leading cancer experts from across the country to obtain interpretation of molecular findings and therapeutic guidance for individual patients.
CMTB Offerings
All cases submitted must have Caris profiling and will be reviewed through one of the following methods:
Cases are uploaded to an online platform where internal and external board members can view and comment on the full patient history, CMI report and pathology report. Specialists work together to review the cases within 7-10 business days to ensure the appropriate diagnostic tests and treatment options are being considered for patients, and the findings are returned to the clinician via email.
CASE
SUBMISSION
Clinical information and key questions submitted
CASE INFORMATION
Relevant patient documents are gathered and de-identified
CASE
OPINION
Case assigned to board members for review
REPORT GENERATION
Board recommendations are returned to OP in PDF format
CAPTURE INFORMATION
Final submissions are stored to inform future recommendations
Caris Molecular Tumor Board Case Studies
The CMTB works one on one with oncologists to obtain interpretation of molecular findings and therapeutic guidance on difficult-to-treat cases. Read how the CMTB approached patients diagnosed with cancer.
Background:
- 78-year-old female
- Remote history of stage IIb breast cancer treated with radical mastectomy and several months of chemotherapy, in remission since the 1990s
- Diagnosed with stage IIb Non-Small Cell Lung Cancer of left upper lobe without nodal positivity or evidence of metastasis
- Patient is status post thoracotomy and left upper lobectomy, presenting for consideration of adjuvant therapy
Discover
More
Whole Exome and Whole Transcriptome Sequencing from Blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
Caris has amassed an industry leading database of molecular and clinical data with more than 500,000 matched patient records. This data enables novel molecular signatures to help improve patient outcomes.
Have Questions?
"*" indicates required fields